Hepatitis E antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Hepatitis E antibodies pairs and antigen for animal health (animal Cat/Feline, Dog/Canine, Fish, Swine/Porcine/Pig, Avian/Bird/Poultry, Deer infectious disease Hepatitis E) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Multiple species disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-VT-P246-Tg001-Ag01	Recombinant Hepatitis E protein	$3090.00
GMP-VT-P246-Tg001-Ab01	Anti-Hepatitis E mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P246-Tg001-Ab02	Anti-Hepatitis E mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P246-Tg001-Ab03	Anti-Hepatitis E human monoclonal antibody (mAb)	$3090.00
GMP-VT-P246-Tg001-Ab04	Anti-Hepatitis E human monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-VT-P246-Tg001-Ag01
Product Name	Recombinant Hepatitis E protein
Pathogen	Hepatitis E
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Hepatitis E antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Hepatitis E level test of animal Cat/Feline, Dog/Canine, Fish, Swine/Porcine/Pig, Avian/Bird/Poultry, Deer infectious disease with Hepatitis E.
Tag	His
Product description	Recombinant Hepatitis E proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P246-Tg001-Ab01,GMP-VT-P246-Tg001-Ab02
Pathogen	Hepatitis E
Product Name	Anti-Hepatitis E mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Hepatitis E antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Hepatitis E antibodies in Hepatitis E level test of animal Cat/Feline, Dog/Canine, Fish, Swine/Porcine/Pig, Avian/Bird/Poultry, Deer infectious disease with Hepatitis E.
Product description	Anti-Hepatitis E mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Hepatitis E antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P246-Tg001-Ab03,GMP-VT-P246-Tg001-Ab04
Pathogen	Hepatitis E
Product Name	Anti-Hepatitis E human monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	Recombinant Hepatitis E antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Hepatitis E antibodies in Hepatitis E level test of animal Cat/Feline, Dog/Canine, Fish, Swine/Porcine/Pig, Avian/Bird/Poultry, Deer infectious disease with Hepatitis E.
Product description	Anti-Hepatitis E mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Pathogen Information

Hepatitis E Virus (HEV) – Unveiling the Intricacies of a Stealthy Pathogen

Hepatitis E Virus (HEV), a member of the Hepeviridae family, is a formidable pathogen that warrants a closer scientific examination. This RNA virus, with its positive-sense, single-stranded genome, holds a distinct place in the virology landscape, predominantly for its role as the causative agent of Hepatitis E. The ramifications of HEV infection span a spectrum of liver-related disorders, encompassing both self-limiting acute hepatitis and, in severe instances, potentially life-threatening conditions.

Classification and Structural Insights

HEV is unequivocally classified as a virus. More specifically, it stands as an RNA virus, characterized by its single-stranded RNA genome with a positive-sense orientation. This designation clearly distinguishes it from both eukaryotic and prokaryotic microorganisms. At its core, HEV reveals a genetic blueprint that encodes essential elements for its replication and infectivity.

The genome of HEV is comprised of multiple Open Reading Frames (ORFs). Among these, ORF1 is of paramount importance, as it encodes non-structural proteins that play vital roles in viral replication and evasion of host defenses. ORF2 is another critical component, responsible for encoding the capsid protein. This capsid protein is pivotal in shaping the virus's architecture, facilitating its entry into host cells, and interacting with the host's immune system. The multifunctional nature of HEV extends to ORF3, which encodes a compact protein with a repertoire of roles in viral infection and pathogenesis.

Hosts and Disease Spectrum

HEV primarily targets humans, initiating the classic manifestation of Hepatitis E. However, an intriguing aspect of this pathogen is its zoonotic potential, enabling cross-species transmission. Animals such as pigs, wild boar, and deer have been identified as potential reservoirs for HEV. This zoonotic capacity adds layers of complexity to the transmission dynamics of the virus.

In humans, HEV infection leads to the development of Hepatitis E, a condition marked by a constellation of symptoms. Jaundice, caused by the buildup of bilirubin due to liver dysfunction, is a hallmark feature. Patients may also experience fatigue, abdominal pain, nausea, and in severe cases, acute liver failure. These symptoms reflect the liver's struggle against the viral onslaught and the ensuing inflammatory response.

In addition to acute hepatitis, HEV can take on a chronic course, particularly in individuals with compromised immune systems. This chronicity can lead to persistent liver inflammation, potentially resulting in cirrhosis over time. Understanding these varied disease outcomes is pivotal for the effective management of Hepatitis E.

Diagnostic Arsenal

The accurate and timely diagnosis of Hepatitis E is a cornerstone of effective disease management. Several diagnostic methods have been developed to detect HEV infection, allowing for precise identification, monitoring, and assessment of treatment efficacy.

Nucleic acid-based methods are instrumental in detecting HEV RNA in clinical specimens. Polymerase Chain Reaction (PCR) serves as a powerful tool, amplifying specific regions of the HEV genome for subsequent identification. This method can target regions such as ORF2 or ORF3, providing high sensitivity and specificity.

Reverse Transcription PCR (RT-PCR) further refines the diagnostic process by converting HEV RNA into complementary DNA (cDNA) before amplification, enhancing sensitivity in detecting viral RNA. Real-Time PCR (qPCR) represents the pinnacle of nucleic acid-based diagnosis, enabling both detection and quantification of HEV RNA, making it suitable for monitoring viral load and treatment response.

Complementary to nucleic acid-based methods are protein-based assays. Enzyme-Linked Immunosorbent Assay (ELISA) is deployed to detect anti-HEV IgM and IgG antibodies in patient serum. The presence of these antibodies indicates recent or past HEV infection. Importantly, these antibodies are predominantly directed against the capsid protein of HEV, highlighting the critical role of this viral component in the immune response.

In conclusion, Hepatitis E Virus, with its RNA-based genome and intricate interplay with host systems, is a pathogen of significance in the realm of infectious diseases. Its capacity for zoonotic transmission, variable disease outcomes, and diagnostic challenges underscore the complexity of this virus. A comprehensive understanding of HEV's classification, genome, clinical impact, and diagnostic methods is crucial for advancing research, diagnosis, and intervention in the fight against Hepatitis E.

About GDU